Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361887 | 0.93 | HCRTR1 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL3363371 | 0.90 | HCRTR1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL3365575 | 0.86 | HCRTR1 (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL3638060 | 0.85 | PTPRB (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL3361282 | 0.85 | PTPRB (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL3055330 | 0.85 | SCN9A (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL3640420 | 0.85 | SCN9A (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL3002225 | 0.82 | HCRTR1 (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL3361393 | 0.82 | LMNA (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL3040044 | 0.82 | LMNA (0.42) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155739-B1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885AAK1 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.